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Synovial macrophages are one of the resident cell types in synovial tissue and while they
remain relatively quiescent in the healthy joint, they become activated in the inﬂamed
joint and, along with inﬁltrating monocytes/macrophages, regulate secretion of pro-
inﬂammatory cytokines and enzymes involved in driving the inﬂammatory response and
joint destruction. Synovial macrophages are positioned throughout the sub-lining layer and
lining layer at the cartilage–pannus junction and mediate articular destruction. Sub-lining
macrophages are now also considered as the most reliable biomarker for disease severity
and response to therapy in rheumatoid arthritis (RA). There is a growing understanding of
the molecular drivers of inﬂammation and an appreciation that the resolution of inﬂam-
mation is an active process rather than a passive return to homeostasis, and this has
implications for our understanding of the role ofmacrophages in inﬂammation.Macrophage
phenotype determines the cytokine secretion proﬁle and tissue destruction capabilities of
these cells. Whereas inﬂammatory synovial macrophages have not yet been classiﬁed
into one phenotype or another it is widely known that TNFα and IL-l, characteristically
released by M1 macrophages, are abundant in RA while IL-10 activity, characteristic of M2
macrophages, is somewhat diminished. Herewewill brieﬂy review our current understand-
ing of macrophages and macrophage polarization in RA as well as the elements implicated
in controlling polarization, such as cytokines and transcription factors like NFκB, IRFs and
NR4A, and pro-resolving factors, such as LXA4 and other lipid mediators which may pro-
mote a non-inﬂammatory, pro-resolving phenotype, and may represent a novel therapeutic
paradigm.
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INTRODUCTION
Macrophages (Mφ) are one of the resident cell types in syn-
ovial tissue, along with ﬁbroblasts. While quiescent in health,
Mφ become activated in the inﬂamed joint, where they make up
around 30–40% of the cellular content, and regulate secretion of
pro-inﬂammatory cytokines and enzymes involved in driving the
inﬂammatory response and joint destruction (Firestein and Zvai-
ﬂer, 1990). Their position throughout the sub-lining layer and
lining layer at the cartilage–pannus junction facilitates their role
mediating articular destruction. It is estimated that rheumatoid
arthritis (RA) and psoriatic arthritis (PsA) each affects approx-
imately 1% of the population (Firestein, 2003; Gladman, 2009),
leading to patient pain and disability as well as contributing to a
great economic burden in terms of lost working days and patient
health services (Cooper, 2000) and therefore is an area of intense
investigation.
As our understanding of inﬂammation progresses, including
the recent concept that resolution of inﬂammation is an active
process rather than a passive return to homeostasis, the role of Mφ
is increasingly appreciated. The inability to resolve acute inﬂam-
mation may lead to a chronic inﬂammatory state. Depending on
their phenotype, Mφ can secrete either pro- or anti-inﬂammatory
cytokines and mediate matrix destruction or deposition. Synovial
Mφparticipate inmanyof the events driving inﬂammation includ-
ing the stimulation of angiogenesis, leukocyte and lymphocyte
recruitment, ﬁbroblast proliferation, and protease secretion lead-
ing to eventual joint destruction (Burmester et al., 1997; Vallejo
et al., 2003; Abeles and Pillinger, 2006). While RA and PsA are
considered more inﬂammatory than osteoarthritis (OA), it can
still contain an inﬂammatory component, of which Mφ play a
large part. In all of these conditions Mφ derived mediators can
drive inﬂammation and cartilage destruction. Depletion of Mφ
from OA synovial cell cultures signiﬁcantly reduced TNFα and
IL-1β levels. Depletion of Mφ from both RA and OA synovial
cell cultures leads to reduced synovial ﬁbroblast responses such as
cytokine and MMP production (Janusz and Hare, 1993; Bonde-
son et al., 2010). Both macrophages and ﬁbroblasts display an
activated cell phenotype with increased cell surface expression
of HLA-DR and leukocyte adhesion molecules (Athanasou et al.,
1988; Alvaro-Gracia et al., 1990) participating in T-cell activation.
Interaction of Mφ with T-cells potentiates the expression of sev-
eral pro-inﬂammatory mediators such as IL-1α and β and MMPs
(McInnes et al., 2000).
Important pro-inﬂammatory cytokines like TNFα and IL-l are
abundant in the inﬂamed synovium and are characteristically
released by classically activated (M1) Mφ. These cytokines are
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central to joint destruction. The importance of Mφ in driving the
inﬂammatory response has been highlighted by several quantita-
tive microscopic studies, where they have shown that Mφ number;
correlates with disease activity (Tak et al., 1997), has potential use
as a biomarker for disease (Kruithof et al., 2006; Bresnihan et al.,
2009) and declines in response to therapy (Goedkoop et al., 2004;
Canete et al., 2010). Mφ can induce angiogenesis (Leibovich et al.,
1987), and hypoxia, a prominent feature of the inﬂamed joint, pro-
motes the survival of monocytes/macrophages and induces their
anaerobic adaptations including glycolysis (Roiniotis et al., 2009).
It is long appreciated that Mφ play an important role in the
pathogenesis of arthritis and this observation was supported by
studies showing that the number of Mφ was increased in clini-
cally affected joints compared to non-affected joints (Kraan et al.,
1998). Several studies also linked the number of synovial Mφ to
inﬂammatory cytokine production joint destruction (Mulherin
et al., 1996). As the search for a reliable biomarker in RA con-
tinued, the role of Mφ was again highlighted. The culmination
of this work has led to sub-lining CD68 positive synovial Mφ
currently being the only validated biomarker for disease severity
(Tak et al., 1997) and response to therapy in arthritis (Haring-
man et al., 2005), further conﬁrming their importance in the
pathogenesis of this disease, a ﬁnding which is independent of
treatment type (Haringman et al., 2005; Thurlings et al., 2008).
Considering the similarities between synovial inﬂammation in
RA and PsA, Mφ have also been proposed as a biomarker for
response to therapy in PsA. Several studies have concluded that
Mφ number is decreased in PsA synovial tissue following ther-
apy (Goedkoop et al., 2004; Kruithof et al., 2006; Canete et al.,
2010).
ACTIVATION OF SYNOVIAL MACROPHAGES
Besides the abundantpro-inﬂammatory cytokines and chemokines
present in inﬂamed synovial tissue, activation, and survival of
Mφ can be achieved through acetylation or de-acetylation of his-
tones. Downstream effects of TNFα and other molecules results
in the induction of histone acetyltransferase (HAT) activity in
Mφ which causes acetylation of histones and subsequent modu-
lation of transcriptional activity. HAT activity is counteracted by
histone deacetylases (HDAC). Two recent studies have found evi-
dence of depressed HDAC activity in RA, particularly in synovial
macrophages and ﬁbroblasts. The ratio of HDAC:HAT activity
was signiﬁcantly lower in RA synovial tissue compare to healthy
controls. In combination with this, HDAC inhibition decreases
IL-10 production from whole tissue synovial explants cultures,
indicating a negative effect on anti-inﬂammatory pathways, which
would lead us to believe that a lack of HDAC may contribute to
perpetuation of inﬂammation (Huber et al., 2007; Grabiec et al.,
2008, 2010). Despite this, HDAC inhibition is showing promise
for inﬂammatory diseases. HDAC inhibitors reduced IL-6 pro-
duction from TNFα stimulated Mφ and induced apoptosis of RA
synovial ﬂuid (SF)Mφ, even in the presence of a pro-inﬂammatory
stimulus (Grabiec et al., 2010). This is of interest considering the
ability of synovial cells and inﬁltrating cells to evade apoptosis
during joint inﬂammation contributing to synovial hypercellular-
ity (Salmon et al., 1997; Perlman et al., 2001). The potential use
of HDAC inhibitors has been further promoted by their success in
suppressing synovial inﬂammation and cartilage destruction in a
CIA mouse model (Nasu et al., 2008).
Toll like receptors (TLR) are pattern recognition receptors that
mediate response to infection. However, it is becoming appar-
ent that some of these receptors may become activated by non-
infectious agents from within the body and may therefore play
a role in autoimmune conditions such as RA. Engagement of
TLRs induces signaling through a well deﬁned pathway involv-
ing MyD88 that leads to transcriptional activation (Joosten et al.,
2003). TLR2 and TLR4 appear to be particularly associated with
RA. TLR knockout and arthritis mouse models, or a combination
of both, have highlighted the position of TLRs in the pathogen-
esis of arthritis. In a model of spontaneous arthritis due to IL-1
receptor antagonist knockout, simultaneous knockout of TLR4
attenuated inﬂammation while TLR2 knockout produced a more
severe arthritis. Knockout of TLR9 had no effect (Abdollahi-
Roodsaz et al., 2008). This clearly indicates a potential beneﬁt
for TLR4 antagonism in RA. However the role of TLR2 seems less
deﬁned as other studies have shown that knockdown of TLR2 pro-
duces beneﬁcial effects in arthritis (Joosten et al., 2003). Further to
this,many TLR ligands have been identiﬁed in synovial inﬂamma-
tion (Okamura et al., 2001; Park et al., 2004). Acute serum amyloid
A (SAA), which is signiﬁcantly upregulated in arthritis and prop-
agates pro-inﬂammatory effects similar to TNFα (O’Hara et al.,
2000; Mullan et al., 2006; Connolly et al., 2011), is a functional lig-
and for TLR2 and may contribute to the deleterious effects of SAA
in arthritis (Cheng et al., 2008). RA Mφ are more responsive to
stimulation than Mφ from other forms of inﬂammatory arthritis,
despite no difference in Mφ number (Huang et al., 2007). There-
fore, engagement of TLR2 and 4 may contribute to Mφ activation
and a sustained Mφ response in RA.
Rheumatoid factor (RF) is one of the diagnostic criteria for
RA and can help to distinguish RA from similar arthropathies like
PsA. Classiﬁcation of RA as an autoimmune disease came initially
from the discovery of IgG auto-antibodies in the blood of patients
(Waaler, 1940; Franklin et al., 1957). RF ismostly IgM-RF,but IgG-
RF and IgA-RF can also be detected in some patients. The cellular
receptors for IgG are the Fcγ receptors, FCγRI (CD64), FcγRII
(CD32), and FcγRIII (CD16). All three receptors are expressed on
synovial Mφ (Laurent et al., 2011) as well as lymphocytes. FcγRIII
has been demonstrated to play a role in the development of arthri-
tis through animal models. Mice deﬁcient in FcγRIII are protected
from the development of collagen induced arthritis without alter-
ation of their humoral response, and therefore the protection is not
due to alterations in T-cell responses (Ståhl et al., 2002; Andrén
et al., 2006). Polymorphisms in Fcγ receptors are associated with
incidence of RA as well as response to therapy (Morgan et al., 2006;
Canete et al., 2009; Thabet et al., 2009; Morales-Lara et al., 2010).
ARE SYNOVIAL MACROPHAGES POLARIZED?
In the immune system Mφ are effective antigen presenting cells
with phagocytic activity which respond to lymphocyte derived
cytokines. However, the responses elicited by Mφ are variable
and depend entirely on the tissue environment. We now know
these responses can be either pro- or anti-inﬂammatory. Dedi-
cated reviews on this topic discuss in more detail the cytokines and
chemokines involved in promoting one phenotype over another
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(Mantovani et al., 2004; Murray and Wynn, 2011) but an overview
of the main components are outlined in Figure 1. Classically
activated M1 Mφ have a pro-inﬂammatory phenotype, produc-
ing high levels of TNFα, IL-1, IL-6, IL-12, IL-23, reactive oxygen
species, and low levels of IL-10. Alternatively activated Mφ, of
which there are three subsets (Mantovani et al., 2004; Martinez
et al., 2008), display and anti-inﬂammatory phenotype, produc-
ing high levels of IL-10, IL-1 receptor antagonist, decoy IL-1RII,
TGFβ, and low levels of IL-12. Both types are necessary for correct
resolution of inﬂammation. An interesting, and potentially useful,
property of these Mφ is that they remain plastic and polarization
into one phenotype does preclude re-polarization (Stout et al.,
2005). Therefore, if we could elucidate the exact pathways and
transcription factors involved in promoting one phenotype over
the other in vivo, this system could be exploited for therapeutic
gain.
There appears to be a lack of evidence for Mφ polarization
in either direction in the inﬂamed joint. It has been suggested
that spondyloarthropathies such as PsA display a more M2 pro-
ﬁle compared to RA patients and that M1 mediators correlate
with joint inﬂammation in RA (Vandooren et al., 2009). However,
in general, most studies of Mφ in arthritis focus on important
Mφ functions and not polarization. The mediators that can con-
trol Mφ polarization are indeed present in the synovium and
some show potential as therapeutic targets. Synovial lining layer
thickness is greater in RA, compared to PsA or healthy control
subjects, which is associated with an increase in synovial Mφ
and ﬁbroblasts. PsA patients tend to have less lining layer Mφ
than RA patients. This has been observed in many comparative
studies. Danning et al. (2000) also found similar levels of IL-10
in RA and PsA synovium, despite the difference in synovial lin-
ing layer Mφ numbers, however levels were described as being
quite low. It is difﬁcult to determine if this lack of IL-10 is a
FIGURE 1 | Blood-borne monocytes exit the blood stream and
differentiate into macrophages.The macrophage response depends on
the stimulus provided by the microenvironment. IFNγ along with LPS or
TNFα drive polarization of M1 (classically activated) macrophages which
participate in pro-inﬂammatory activities. On the other hand, IL-4+ IL-13,
IL-10, or immune complexes drive M2 (alternatively activated)
macrophages, which participate in anti-inﬂammatory responses.
contributor to or consequence of the overwhelming inﬂamma-
tion in the joint. A study by Mottonen et al. (1998) found that
68% of Mφ isolated from RA SF were CD86 positive and that SF
Mφ can take on a dendritic cell phenotype when exposed to a
combination of IL-4 and GM-CSF and that these cells were more
effective at activating T-cells than control or TNFα stimulated
Mφ. The effects of IL-4+GM-CSF were mediated through CD86,
a marker of classically activated Mφ. IL-10 was able to inhibit
the observed effects with IL-4+GM-CSF as it downregulated the
expression of CD86, as well as CD-40 and HLA-DR which also
participate in Mφ mediated T-cell activation. This is consistent
with the classiﬁcation that M2c Mφ, which are driven by IL-10
are involved in suppression of the immune response (Mantovani
et al., 2004). These results may appear confusing as IL-4 along with
IL-13 drive the M2a or alternative Mφ phenotype which should
be involved in anti-inﬂammatory responses. However GM-CSF
drives the M1 phenotype in monocyte derived macrophages so
this may be the driving force for inﬂammatory responses in these
experiments.
WHAT REGULATORS IN SYNOVIAL INFLAMMATION COULD
POTENTIALLY INFLUENCE MACROPHAGE POLARIZATION?
Figure 1 has outlined the cytokines and regulators that promote
M1 or M2 polarization. The extent of expression of these factors in
the joint varies. The M1 Mφ phenotype is induced by interferon-
γ (IFNγ) in combination with either lipopolysaccharide (LPS)
or TNFα. IFNγ is highly expressed in RA synovial tissue and its
levels signiﬁcantly correlate with disease severity (Milman et al.,
2010). Exposure to INFγ increases the response of Mφ exposed to
other stimuli by either upregulating pro-inﬂammatory cytokines,
like TNFα, or downregulating anti-inﬂammatory cytokines, like
IL-10 (Erwig et al., 1998; Wallet et al., 2010). TNFα is a mas-
ter cytokine in inﬂammation and as such is a potent inducer of
other pro-inﬂammatory cytokines (Nawroth et al., 1986; Butler
et al., 1995), is chemotactic for leukocytes, is a potent inducer of
angiogenesis (Leibovich et al., 1987), stimulates adhesion mole-
cule expression in SFC in vitro (Marlor et al., 1992), and lymphoid
migration into inﬂamed synovial tissue in vivo (Wahid et al., 2000).
Within the inﬂamed joint macrophages, ﬁbroblasts, lymphocytes,
and endothelial cells produce TNFα. An important role for TNFα
in arthritis was conﬁrmed by studies which showed its potential
to degrade both cartilage (Dayer et al., 1985) and bone (Bertolini
et al., 1986). Further rationale for the involvement of TNFα in
the progression of inﬂammatory arthritis was provided when
transgenic mice expressing a modiﬁed human TNFα gene spon-
taneously developed arthritis which exhibited increased human
TNFα protein, joint inﬂammation, bone erosion, and cartilage
destruction. In this study, antibodies speciﬁc for human, but not
mouse TNFα reduced disease severity (Keffer et al., 1991). In sub-
sequent studies administration of amonoclonal antibody to TNFα
ameliorated inﬂammation and joint damage after disease onset in
a CIA model of arthritis (Williams et al., 1992). TNFα cytokine
targeted therapies have now been developed for inﬂammatory
arthritis. The ﬁrst clinical trial was undertaken in the UK in 1992
and demonstrated that targeted biologic therapy decreased serum
IL-6 levels, swollen joint numbers and levels of the acute phase pro-
teins CRP and A-SAA which are markers of inﬂammation (Elliott
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et al., 1993). Alternatively, anti-inﬂammatory and M2 polarizing
cytokines like IL-10 are lowly expressed in arthritis as its signal-
ing is blocked during FCγ receptor ligation (Ji et al., 2003), and
treatment with the pro-resolving mediator annexin A1 stimulates
release of IL-10 (Ferlazzo et al., 2003). Treatment of PBMC with
IL-10 caused a change in the ratio of Th17:Treg cells in favor of Treg
cells and decreased production of the pro-inﬂammatory cytokine
IL-17 (Heo et al., 2010). Animal models of arthritis have also
demonstrated how treatmentwith IL-10 can suppress the develop-
ment and progression of joint inﬂammation, even in established
disease (Walmsley et al., 1996; Whalen et al., 1999; Mauri et al.,
2003).
The cytokines involved in promoting polarization are well
deﬁned, however less is known about which transcription factors
are utilized to induce polarization. IRF5 (interferon regulatory
factor 5) has been implicated in driving the M1 phenotype as
well as actively suppressing M2 polarization and driving Th1 and
Th17 responses (Krausgruber et al., 2011). While the study by
Krausgruber et al. (2011) was not performed in synovial Mφ, ani-
mal studies suggest that inﬂammation in RA is driven by Th1
cytokines such as IFNγ, which is upregulated early in the dis-
ease process (Miltenburg et al., 1992; Schulze-Koops and Kalden,
2001) and a rapid growth in interest in the Th17 pathway and
indeed IL-17 itself in the last few years would suggest that this
would warrant investigation in the inﬂamed joint. Recent reports
conﬁrm that alterations in the IRF5 gene confers susceptibility to
RA (Dieguez-Gonzalez et al., 2008; Han et al., 2009; Dawidowicz
et al., 2011) as well as many related illnesses such as inﬂammatory
bowel disease,Sjogrens syndrome,and systemic lupus erythemato-
sus (Dideberg et al., 2007; Graham et al., 2007; Miceli-Richard
et al., 2007). Other transcription factors in the IRF family, like
IRF3 (Biswas et al., 2006) and IRF4 (Satoh et al., 2010) have been
implicated in promoting Mφ polarization in other disease set-
tings, and IRF family members contribute to determination of
dendritic cell fate (Tamura et al., 2005). These ﬁndings make the
IRF family attractive candidates to study in the context of Mφ’s in
arthritis.
NR4A is part of the orphan nuclear receptor superfamily which
have roles in lipid metabolism and inﬂammation (Desreumaux
et al., 2001; Oosterveer et al., 2010; Hong et al., 2011). Receptors
in the same superfamily as NR4A are downregulated in arthritic
tissue and their activation appears to play a role in inhibiting dis-
ease progression (Bonnelye et al., 2008; Park et al., 2010). However
members of theNR4A subfamily appear to have less clearly deﬁned
effects to the anti-inﬂammatory family members liver X receptor
and peroxisome-proliferator-activator receptor and drive inﬂam-
mation in human synovial tissue (Murphy et al., 2001). The role of
NR4A receptors speciﬁcally in Mφ polarization has not yet been
elucidated, however, any role for NR4A in Mφ polarization would
be an interesting ﬁnding due to the modulation of NR4A by both
dexamethasone and methotrexate, which are effective treatments
for joint inﬂammation in some patients. NR4A receptors can also
activate NFκB in murine Mφ (Pei et al., 2006) where it promotes
transcription of pro-inﬂammatory genes. In arthritis, and inﬂam-
mation in general, NFκB can be considered a master transcription
factor as it is utilized by many ligand–receptor complexes to mod-
ulate gene transcription. TNFα and IL-1β which are abundant in
the inﬂamed joint employ this transcription factor and in turn
can be regulated by it. NFκB activation has been detected prior to
the clinical onset of arthritis in animal models (Tsao et al., 1997;
Han et al., 1998) and the NFκB pathway has been directly targeted
as a treatment method for RA conﬁrming its essential role in the
pathogenesis of this disease (Wakamatsu et al., 2005). Immuno-
histochemical staining has conﬁrmed nuclear expression of NFκB
subunits in synovial Mφ (Handel et al., 1995). The NFκB family
consists of ﬁve proteins; p50, p52, RelA (p65), RelB, and c-Rel.
These proteins form homo or heterodimers to determine gene
transcription. RelA, RelB, and c-Rel contain a transcriptional acti-
vation domain and therefore upregulate gene expression, however
p50 and p52 do not contain the transcriptional activation domain
and homodimers of these proteins can sometimes have a repress-
ing function (Bohuslav et al., 1998). NFκB p50 activation has been
linked to promoting M2 polarizing genes in Mφ (Porta et al.,
2009). This study found that knockout of the NFκB p50 subunit
prevented the development of tolerance in LPS challenged Mφ by
restoring M1 mediators and inhibiting M2 cytokines. Similarly,
Saccani et al. (2006) found that accumulation of the p50 homod-
imer occurred in the nuclei of tumor associated Mφ and that these
Mφ expressed an M2 phenotype. Therefore due to the prominence
of the NFκB pathway in RA it remains an interesting candidate for
inﬂuencing Mφ polarization. A summary of all factors discussed
here are outlined in Table 1.
MACROPHAGES AND RESOLUTION OF INFLAMMATION
There is a growing understanding of the molecular drivers of
inﬂammation and an appreciation that the resolution of inﬂam-
mation is an active process rather than a passive return to
homeostasis. Endogenously produced mediators that actively pro-
mote the resolution of inﬂammation are now under investigation
Table 1 | Description of the regulators in synovial inflammation that
could potentially influence macrophage polarization.
Polarizing factors Mφ subset promotion Reference
CYTOKINES
IFNγ+ (LPS/TNFα) M1 Erwig et al. (1998),
Wallet et al. (2010)
IL-4+ IL-13 M2 See review Mantovani
et al. (2004)
IL-10 M2 See review Mantovani
et al. (2004)
Immune complexes M2 See review Mantovani
et al. (2004)
TRANSCRIPTION FACTORS
IRF3 M2 Biswas et al. (2006)
IRF4 M2 Satoh et al. (2010)
IRF5 Promotes M1, actively
inhibits M2
Krausgruber et al.
(2011)
NFκB p50 M2 Porta et al. (2009),
Biswas et al. (2006)
NR4A Not yet investigated in
Mφ polarization
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for their therapeutic use. These are molecules such as lipoxins,
resolvins, protectins, and annexins. Lipoxin A4 (LXA4) is an
eicosanoid produced by the transcellular metabolism of arachi-
donic acid by 15/5- or 5/12-lipoxinagese (Serhan et al., 1984). Its
biosynthesis is co-incident with the resolution phase of inﬂam-
mation and many of its bioactions are mediated through ligation
of its receptor, ALX/FPR2 (Fiore et al., 1994). LXA4 is produced
in inﬂamed synovial tissue (Thomas et al., 1995) where it can
downregulate pro-inﬂammatory activities of activated ﬁbroblasts
and upregulate anti-inﬂammatory activities, even in the presence
of a pro-inﬂammatory stimulus which acts through the same
receptor (Sodin-Semrl et al., 2004; Kronke et al., 2009; Chan and
Moore, 2010). In other disease models, LXA4 has been shown to
induce anti-inﬂammatory/pro-resolving actions such as inhibi-
tion of neutrophil recruitment and activation (Filep et al., 1999),
regulation of NFκB activation (Decker et al., 2009), and the clear-
ance of apoptotic cells by Mφ (Godson et al., 2000). Neutrophils
are the ﬁrst effector cells at the site of inﬂammation. Once these
cells have carried out their functions in regard to host defense they
are programmed to die by apoptosis. Resolution of inﬂamma-
tion and return to homeostasis involves phagocytosis of apoptotic
neutrophils to prevent the persistence to necrosis and leakage of
cellular contents, which may itself begin an inﬂammatory reac-
tion. Despite the lack of apoptosis occurring in all cell types in
the inﬂamed synovium, resident synovial Mφ retain the capacity
to phagocytose apoptotic cells, even at an early timepoint after
arthritis induction (van Lent et al., 2001). If normal apoptosis and
phagocytosis could be induced in the inﬂamed synovium, possi-
bly by native LXA4 or its stable analogs, this process may trigger a
normal resolution of inﬂammation.
In order to encourage phagocytosis, apoptotic cells release
mediators that attract phagocytes toward them, essentially ﬂag-
ging themselves for engulfment. One such mediator is the anti-
inﬂammatory compound annexin A1 (Arur et al., 2003; Scannell
et al., 2007). Annexin A1 is a 37-kDa protein of the annexin super-
family where all family members contain a similar core region and
a distinct N-terminal region which confers speciﬁcity of function.
Generally annexin A1 is localized to the cytoplasm where, upon
stimulation, it is mobilized to the cell membrane and secreted
(for an extensive review on annexin A1 see Perretti and Dalli,
2009). Interestingly annexin A1 also signals through ALX/FPR2,
the same receptor utilized by LXA4 and SAA.AnnexinA1 is widely
expressed in many cell types including Mφ. Immunohistochemi-
cal analysis has demonstrated an increased expression of annexin
A1 in the RA synovial lining layer macrophages and ﬁbroblasts
compared to OA and normal joints. This may, however, be due
to the increased lining layer thickness in this condition (Gould-
ing et al., 1995) as other studies have shown decreased binding
of annexin A1 to several cell types in RA (Goulding et al., 1992;
Sampey et al., 2000). Glucocorticoid stimulation causes annexin
A1 mobilization to the cell surface and secretion where it medi-
ates glucocorticoid induced anti-inﬂammatory effects. This is of
particular interest in arthritis as glucocorticoid therapy is one of
the current treatments for this condition (Flower, 1988; Podgorski
et al., 1992; Yang et al., 1998, 1999; Maderna et al., 2005). However,
as is increasingly the case for many mediators, the role of annexin
A1 may not be as unambiguous as initially described and it may
also potentiate pro-inﬂammatory actions in arthritis. An inves-
tigation by Tagoe et al. (2008) has revealed synergistic actions
with TNFα and annexin A1 in terms of MMP production from
synovial ﬁbroblast cells. They saw ﬁrstly that TNFα can induce
expression of endogenous annexin A1 and secondly that TNFα
along with the annexin A1 mimetic peptide Ac2-26 enhanced
secretion of MMP-1 which was dependent on FPR2/ALX, Erk,
Jnk, and NFκB (Tagoe et al., 2008). As mentioned, this study
was not performed in synovial Mφ, but as they have similar
actions to synovial ﬁbroblasts, the same results may be produced
by these cells once investigated. Further to this, it has also been
shown that administration of human recombinant annexin A1
during the immunization phase of the collagen induced arthritis
model perpetuated the development of the signs and symptoms
of arthritis. This may have been due to the increased T-cell activa-
tion and skewing toward a Th1 phenotype by annexin A1 acting
through FPR2/ALX (D’Acquisto et al., 2007). T-cells from RA
patients 48 h post steroid therapy demonstrated depressed expres-
sion of annexin A1 (D’Acquisto et al., 2008) further lending
support to the possibility that annexin A1 may also mediate pro-
inﬂammatory actions. However we must be careful to acknowl-
edge the actions of speciﬁc cleavage products from full length
annexin. One such cleavage product has been identiﬁed as caus-
ing neutrophil extravasation, an important event in inﬂammation,
where other truncated forms of annexin cannot (Williams et al.,
2010).
CONCLUSION
In the study of inﬂammation and our efforts to promote its normal
resolution, Mφ remain to the fore of our interest. In the inﬂamed
joint, Mφ will continue to be a focal point for therapeutic inter-
vention which, currently, centers around cytokine blockade but
now has the possibility of extending into Mφ re-programming.
This remains an interesting and a yet to be fully explored option
in terms of treatment for synovial inﬂammation.
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